Arizona State Retirement System Buys 482 Shares of Illumina, Inc. (NASDAQ:ILMN)

Arizona State Retirement System grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,122 shares of the life sciences company’s stock after acquiring an additional 482 shares during the period. Arizona State Retirement System’s holdings in Illumina were worth $6,163,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Proficio Capital Partners LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $10,875,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after acquiring an additional 296 shares in the last quarter. Keybank National Association OH raised its stake in shares of Illumina by 52.4% during the fourth quarter. Keybank National Association OH now owns 392,014 shares of the life sciences company’s stock valued at $52,385,000 after acquiring an additional 134,862 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Illumina by 4.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 683,545 shares of the life sciences company’s stock valued at $91,342,000 after acquiring an additional 25,991 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Illumina by 57.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,182 shares of the life sciences company’s stock valued at $158,000 after buying an additional 431 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ILMN shares. Royal Bank of Canada cut their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Piper Sandler lifted their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Stephens lifted their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Price Performance

Shares of ILMN opened at $86.62 on Friday. The firm has a market capitalization of $13.72 billion, a PE ratio of -11.28, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66. The company’s fifty day moving average price is $118.38 and its 200-day moving average price is $131.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.